Linked Life Data

18418220

Source:http://linkedlifedata.com/resource/pubmed/id/18418220

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-4-17
pubmed:abstractText
A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/m2 and oxaliplatin 100 mg/m2 both infused on day 1. A prophylactic 5-day course of human granulocyte colony-stimulating factor 5 microg/kg/day was given subcutaneously, and erythropoietin (10,000 IU subcutaneously three times per week) was administered if hemoglobin was less than 12.0 mg/dl. The confirmed overall response rate was 34%, including two complete responses (6%) and 10 partial responses (28%). Fifteen patients (43%) had stable disease. The median time to response was 2.5 months (1-3.5), the median time to progression was 8.9 (4-42.5) months and the median overall survival time was 11.6 (2.5-51) months. Hematologic toxicity was common, though World Health Organization grade 3 or 4 neutropenia occurred only in six (17%) patients and anemia in six (17%) patients, respectively. Nonhematologic adverse reactions were usually mild-to-moderate. Our data suggest that the combination of docetaxel and oxaliplatin with granulocyte colony-stimulating factor and erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal adenocarcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0959-4973
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
535-9
pubmed:meshHeading
pubmed-meshheading:18418220-Adenocarcinoma, pubmed-meshheading:18418220-Adult, pubmed-meshheading:18418220-Aged, pubmed-meshheading:18418220-Anemia, pubmed-meshheading:18418220-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18418220-Drug Administration Schedule, pubmed-meshheading:18418220-Erythropoietin, pubmed-meshheading:18418220-Esophageal Neoplasms, pubmed-meshheading:18418220-Female, pubmed-meshheading:18418220-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:18418220-Humans, pubmed-meshheading:18418220-Infusions, Intravenous, pubmed-meshheading:18418220-Injections, Subcutaneous, pubmed-meshheading:18418220-Male, pubmed-meshheading:18418220-Middle Aged, pubmed-meshheading:18418220-Neutropenia, pubmed-meshheading:18418220-Organoplatinum Compounds, pubmed-meshheading:18418220-Stomach Neoplasms, pubmed-meshheading:18418220-Survival Rate, pubmed-meshheading:18418220-Taxoids
pubmed:year
2008
pubmed:articleTitle
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
pubmed:affiliation
Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. michael.hejna@meduniwien.ac.at
pubmed:publicationType
Journal Article, Clinical Trial, Phase II